The Claim
Among US veterans with pre-existing substance use disorders and type 2 diabetes, initiation of GLP-1 receptor agonists is associated with a 31% lower risk of substance use disorder-related emergency department visits, a 26% lower risk of SUD-related hospital admissions, and a 50% lower risk of SUD-related mortality over a three-year period compared to initiation of SGLT-2 inhibitors, suggesting potential harm reduction benefits.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For US veterans with diabetes and substance use issues, taking GLP-1 drugs (like Ozempic) might lower their chances of ending up in the ER, being hospitalized, or dying from substance-related problems compared to those taking a different diabetes drug called SGLT-2 inhibitors.
See the scientific wording
Among US veterans with pre-existing substance use disorders and type 2 diabetes, initiating GLP-1 receptor agonists is associated with a 31% lower risk of SUD-related emergency department visits, a 26% lower risk of SUD-related hospital admissions, and a 50% lower risk of SUD-related mortality over three years compared to initiating SGLT-2 inhibitors, indicating potential harm reduction benefits.
What the research says
1 studyThe study found that veterans with diabetes and substance use issues who started GLP-1 drugs had fewer emergencies, hospital stays, and deaths related to substance use compared to those who started a different diabetes drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.